NASDAQ: LIVN · Medical Devices
LivaNova (LIVN) fair value and price range
As of 26 Sep 2026, Faircurve's model values LivaNova (LIVN) at $76.95 a share. The stock last closed at $75.07, which puts the model's fair value 2.5% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 2 Oct 2026. LivaNova PLC.
Faircurve Insights · 26 Sep 2026
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions, operating through three key segments.
Faircurve's model valued LivaNova PLC at $76.95 a share on 26 Sep 2026, the midpoint of 2,000 simulations. The fair value moved -1.8% from the previous run on 19 Sep 2026, which gave $78.34. The calibrated range over 63 trading days is $64.56 to $93.83, built from the fair value, since there is no live options data for the stock. Ranges built this way held the price 60% of the time at this horizon, and the model grades the evidence behind this valuation as low.
Faircurve's model compares LivaNova PLC with Integer Holdings Corporation (ITGR), Haemonetics Corporation (HAE), Neogen Corporation (NEOG), UFP Technologies, Inc. (UFPT), Glaukos Corporation (GKOS), and Insulet Corp. (PODD). The stock's moves around its last 8 earnings reports show a median size of 12.5%, ignoring direction.
Written from the figures on this page for the 26 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give LIVN?
The calibrated range for LIVN over 63 trading days is $64.56 to $93.83. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $49.22 to $118.64. In 50% of the simulations the fair value came out above the price the model ran on.
How does LIVN compare with similar companies?
The companies in medical devices closest to LivaNova in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| ITGR Integer Holdings Corporation | $126.45 | $118.83 | -6.0% | Fairly valued |
| HAE Haemonetics Corporation | $104.68 | $106.81 | +2.0% | Fairly valued |
| NEOG Neogen Corporation | $12.15 | $12.06 | -0.7% | Fairly valued |
| TMDX TransMedics Group, Inc. | $79.80 | $85.59 | +7.3% | Low evidence grade |
| UFPT UFP Technologies, Inc. | $300.70 | $275.24 | -8.5% | Fairly valued |
| INSP Inspire Medical Systems, Inc. | $69.97 | $70.21 | +0.3% | Low evidence grade |
| GKOS Glaukos Corporation | $163.75 | $147.85 | -9.7% | Fairly valued |
| PODD Insulet Corp. | $131.69 | $142.34 | +8.1% | Fairly valued |
When does LIVN report earnings, and how has the stock reacted?
LivaNova's next earnings report is scheduled for 4 Nov 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 5.6% in either direction through the nearest expiry, about 13 days out. That is the size the market is pricing, not a direction.
How LIVN moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 12.5%.
| Report date | Two session move |
|---|---|
| 5 Aug 2026 | -11.2% |
| 6 May 2026 | +23.2% |
| 25 Feb 2026 | +2.8% |
| 5 Nov 2025 | -8.1% |
| 6 Aug 2025 | +13.9% |
| 7 May 2025 | +27.4% |
| 25 Feb 2025 | -16.3% |
| 30 Oct 2024 | -2.5% |
LivaNova at a glance
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments.
- Market value
- $4.2B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $1.6B
- Consensus revenue growth, next fiscal year
- +9.8%
- Analysts with estimates
- 6
- Beta to the US market
- 0.82
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices LivaNova on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for LIVN was $78.34. As of 26 Sep 2026 it is $76.95, a change of -1.8%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about LivaNova's valuation
Is LivaNova stock undervalued or overvalued?
Faircurve's model puts LIVN's fair value at $76.95 a share against a last close of $75.07, as of 26 Sep 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is LIVN's fair value?
$76.95 a share as of 26 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $49.22 to $118.64.
What price range does the model give LIVN?
$64.56 to $93.83 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does LivaNova report earnings next?
The next report is scheduled for 4 Nov 2026. Companies can move their dates.
How much has LIVN moved on past earnings reports?
Across its last 8 reports the median two session move was 12.5%, ignoring direction. The largest was +27.4% around the report of 7 May 2025.
How confident is the model in this valuation?
The model's evidence grade for LIVN is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.